A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
Clinics
;
71(10): 586-592, Oct. 2016. tab, graf
Article
in English
| LILACS
| ID: lil-796864
ABSTRACT
OBJECTIVES:
To compare the efficacy and safety of two filgrastim formulations for controlling chemotherapy-induced neutropenia and to evaluate the non-inferiority of the test drug relative to the originator.METHODS:
This phase III non-inferiority study had a randomized, multicenter, and open-label design. The patients were randomized at a ratio of 11 with a follow-up period of 6 weeks for each patient. In both study arms, filgrastim was administered subcutaneously at a daily dose of 5 mg/kg body weight. The primary endpoint was the rate of grade 4 neutropenia in the first treatment cycle. The secondary endpoints were the duration of grade 4 neutropenia, the generation of anti-filgrastim antibodies, and the rates of adverse events, laboratory abnormalities, febrile neutropenia, and neutropenia of any grade.RESULTS:
The primary efficacy analysis demonstrated the non-inferiority of the test drug compared with the originator drug; the upper limit of the 90% confidence interval (CI) for the rate of neutropenia between the two groups (12.61%) was lower than the established margin of non-inferiority. The two treatments were similar with respect to the secondary endpoints and safety.CONCLUSION:
The efficacy and safety profile of the test drug were similar to those of the originator product based on the rate of grade 4 neutropenia in the first treatment cycle. This study supports Anvisa’s approval of the first biosimilar drug manufactured by the Brazilian industry (Fiprima¯).
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Breast Neoplasms
/
Biosimilar Pharmaceuticals
/
Filgrastim
/
Hematologic Agents
/
Neutropenia
Type of study:
Controlled clinical trial
Limits:
Adult
/
Female
/
Humans
Language:
English
Journal:
Clinics
Journal subject:
Medicine
Year:
2016
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Hospital Pérola Byington/BR
Similar
MEDLINE
...
LILACS
LIS